ALK and non-small cell lung carcinoma: In current study, we discovered RNase1-driven-ALK-activation (RDAA) as a novel oncogenic driver in NSCLC, elucidated its oncogenic mechanisms, and explored an effective targeted therapy strategy targeting RDAA through preclinical experiments and small clinical therapeutic trials.